Dash Bio is a modern, automated platform designed to deliver high-quality and dramatically accelerated clinical bioanalysis. Dash Bio leverages AI, robotics, and fully integrated software to transform the way drugs are brought to market by enabling faster, more reliable bioanalytical testing for clinical trials.
The company's core offering is an automated system for clinical bioanalysis—the testing of samples from clinical trial subjects. By automating critical laboratory steps, Dash Bio supports assays from in vivo studies through full clinical trials, reducing the time and cost associated with bringing new therapies to patients. Their technology delivers assay turnaround times up to 10x faster than industry norms, while maintaining or improving assay quality. This positions Dash Bio as a potential game-changer in clinical research and drug development.
How Was Dash Bio Started?
Dash Bio was founded by a team with deep expertise in biotechnology, automation, and artificial intelligence. The leadership includes Dave Johnson (CEO, formerly Chief Data and AI Officer at Moderna), Ander Tallett (COO, who led Enterprise Systems at Moderna and Resilience), and Ely Porter (CSO, Co-founder and CTO of Rootpath). Their combined backgrounds in biopharma innovation, automation, and data science inform Dash Bio's mission to reinvent bioanalysis for clinical research. You can learn more about their mission on their About page.
What Makes Dash Bio Different?
Dash Bio differentiates itself by:
- Automating and integrating the entire bioanalysis workflow using AI and robotics.
- Delivering significantly faster turnaround times—up to 10x faster than industry standards.
- Supporting end-to-end needs from preclinical in vivo assays through clinical trial sample analysis.
- Aiming to reduce costs and speed up the path to market for new therapies, while maintaining high-quality standards for Good Laboratory Practice (GLP) and clinical studies.
Who Uses Dash Bio?
Dash Bio primarily serves organizations involved in clinical drug development, such as pharmaceutical and biotechnology companies, clinical research organizations (CROs), and research teams running GLP or clinical studies. By accelerating bioanalysis, Dash Bio helps these organizations improve research timelines and reduce operational bottlenecks in the drug development process.
Who Are Dash Bio's Competitors?
Dash Bio operates in the clinical bioanalysis and laboratory automation space, where traditional central labs and specialized CROs provide bioanalytical services. Competitors may include established bioanalytical labs, as well as newer entrants leveraging technology and automation to improve assay workflows. Dash Bio's focus on fully integrated automation and AI aims to set it apart from more manual or partially automated providers.
Leadership Team
- Dave Johnson, CEO (Former Chief Data and AI Officer at Moderna)
- Ander Tallett, COO (Led Enterprise Systems at Moderna and Resilience)
- Ely Porter, CSO (Co-founder and CTO of Rootpath)
Use PromptLoop to Uncover Company Data
Looking for more company insights like this? PromptLoop helps you go deeper, providing unique data points and analysis on companies like Dash Bio and many others. Automate your research and find the information that matters most. Discover how PromptLoop can accelerate your market intelligence. Get A Free Demo to learn more.